A Limerick based unit of US healthcare giant Johnson & Johnson (J&J) returned to profit last year to record pre-tax profits of €501.69m.
Johnson & Johnson Vision Care Ireland UC employs 1,632 at its base at the National Technology Park (NTP) in Limerick where it produces eye care products.
Across Ireland, J&J employs more than 6,000 in 10 sites in five counties, Cork, Dublin, Limerick, Galway and Mayo.
The new accounts show that Johnson & Johnson Vision Care Ireland UC returned to profit as revenues rose by 15% from €1.2 billion to €1.38 billion.
The directors state that they expect that the present level of activity will remain for the foreseeable future.
They also state that the increase in revenue was predominantly driven by increased demand in the global market.
The firm recorded a pre-tax loss of €792.9m in 2024 after incurring an exceptional €1.06 billion expense arising from it reaching a new pricing agreement with Irish and US tax authorities.
The firm last year paid out a dividend of €1.1 billion to parent firm, Janssen Pharmaceutical UC.
In 2025, Johnson & Johnson Vision Care UC last year benefited from €2 billion in income in investment from subsidiaries and this was largely cancelled out by a €1.9 billion impairment of investments in a subsidiary.
The connected income and impairment arise from a company subsidiary, Vision Care Finance UC being placed into liquidation on September 30, 2025.
A note states that prior to the liquidation, the company recognised investment income of €2 billion in respect of distributions received from the subsidiary.
On the 2025 performance, the directors state that despite ongoing competitive challenges in the marketplace, they are satisfied that they will be able to manage the company’s activities to enable it to continue trading profitably into the future.
The company recorded post tax profits of €427.56m after incurring a €74.12m corporation tax charge.
Numbers employed last year declined from 1,658 to 1,632 made up of 1,556 in manufacturing and product and 76 in administration.
Last year, staff costs decreased from €169.39m to €161.24m that included wages and salaries of €131.28m and share based payments of €2.14m.
Pay to directors more than doubled from €1.02m to €2.5m made up of emoluments of €2.5m and €55,000 in gains on share options exercised.
The profit takes account of non-cash depreciation charges of €98.35m, R&D costs of €10.9m offset by R&D tax credits of €3.2m. Profits were hit by a €10.67m non-cash impairment of fixed assets.
Shareholder funds at the end of December 2025 totalled €1.89 billion that included accumulated profits of €1.73 billion.
Reporting by Gordon Deegan

